drugs
-
19 Oct
Drug consumption rooms: government approved ways to get high are making drugs safer
Located near the Gare de Nord in Paris is France’s main open drug scene.
-
4 Sep
More speciality drugs are coming onto the market than ever before. Why?
The number of drugs picking up a designation from regulators — first treatments or speciality drugs — across the European Union, the US, and Japan have risen by 117 percent in 10 years.
-
25 Aug
Are FDA expedited drug reviews delivering rapid health benefits or unnecessary risks?
The FDA has been on the right track when taking forward promising pipeline drugs for expedited new drug application (NDA) review.
-
9 Aug
Pharmaceutical scandals: US states are suing the OxyContin manufacturer
The US states of New Hampshire and South Carolina are suing Purdue Pharma, the manufacturer of OxyContin for its role in the opioid crisis.
-
31 Jul
Helpless and homeless — bad business practices are the tip of the iceberg
A Marks and Spencer caught some heat last week for installing a high-pitched alarm to deter people from sleeping around its premises.
-
30 May
A new drug class could be set to reduce migraine misery
A breakthrough in migraine treatment is expected to create a $5bn dollar industry and improve the lives of millions of sufferers worldwide.
-
26 May
Antibiotic resistance: Could we be looking at the death of medicine?
Heart surgery, prenatal care, organ transplants, and blood transfusions.
-
17 May
Brexit: Liberal Democrats promise second EU referendum
The Liberal Democrat manifesto will offer the British public a chance to reverse Brexit.
-
27 Apr
NHS funding crisis: If pharmaceutical giants leave the UK, what could it mean for the economy?
Some of the world’s biggest drug companies warned that they will withdraw from the UK market if the NHS does not receive an extra £20bn a year.
-
1 Feb
Moving biopharma manufacturing back to the US will take years – Here’s why
US president Donald Trump’s insistence that manufacturing move back to the US has sparked a wave of promises from big biopharma firms over the sector’s future.
-
1 Feb
Trump’s all talk: drug prices will continue to rise in the US
Global pharmaceutical stock indices rose by up to 12 percent after Donald Trump’s US election victory in November.
-
17 Jan
The ups and downs of clinical trials: Don’t write off Pfizer’s failed growth hormone just yet
When it comes to clinical trials, sometimes the results aren’t completely clear.
-
12 Jan
Japan’s Takeda is buying Ariad Pharma for $5.2bn — Is this deal a bellwether for the biotech industry in 2017?
Given the scarcity of commercially-ready oncology assets, cancer drugs are appealing to big pharma with lots of cash and high prices are being paid for hopeful products.